In-vitro and in-vivo availability of mebeverine hydrochloride suppositories

Scientia Pharmaceutica

Volumn 74, Issue 1, 2006, Pages 31-51

  Al Dossary, Basmah N ^a   Al Gohary, Omaimah M N ^a   El Khawaas, Manal M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Enhancers; HPLC; in vitro and in vivo availability; Mebeverine hydrochloride; Suppositories

Indexed keywords

MEBEVERINE; WITEPSOL H 15;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG RELEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RABBIT; SUPPOSITORY; TABLET;

EID: 33750737742     PISSN: 00368709     EISSN: 22180532     Source Type: Journal    
DOI: 10.3797/scipharm.2006.74.31     Document Type: Article

References (42)

1. Product information: Mebeverine, Training Manual. Duphar B.V., The Netherlands, (1991).
2. Schaffstein W, Panijel M, Luttecke K. Comparative safety and efficacy of trimebutine versus mebeverine in the treatment of irritable bowel syndrome. Curr. Ther. Res. 1990; 47(1): 136-45.
3. Connel AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br. Med. J. 1965; 2: 848-51.
4. Linder A, Selzer H, Classen V, Gans P, Offringa OR, Zwagemakers JMA. Pharmacological properties of mebeverine, a smooth muscle relaxant. Arch. Inter. Pharmacodyn. 1963; 145: 378-95.
5. MEPPO: The Middle East Drug Compendium. OVP Healthcare Publications SA, Paris, France, 1999; p. 166.
6. Hosny EA, Al-Gohary OMN. Release kinetics and availability of mebeverine hydrochloride from polycarbophil loaded by swelling. Drug Dev. Ind. Pharm., 1994; 20(16): 2593-605.
7. Dickinson RG, Baker PV, Franklin ME, Hooper WD. Facile hydrolysis of mebeverine in vitro and in vivo: negligible circulating concentrations of the drug after oral administration. J. Pharm. Sci., 1991; 80(10): 952-57.
8. Williams FM, Clinical significance of esterases in man. Clin. Pharmacok., 1985; 10: 392-403.
9. Kristinsson J, Snorradottir I, Johannson M. The metabolism of mebeverine in man: identification of urinary metabolites by gas chromatography/mass spectrometry. Pharmacol. Toxicol., 1994; 74(3): 174-80.
10. Tulich LJ, Randall JL, Kelm GR, Wehmeyer KR. Determination of two mebeverine metabolites, mebeverine alcohol and desmethylmebeverine alcohol, in human plasma by a dual stable isotope-based gas chromatographic-mass spectrophometric method. J. Chromatog. Biomed. Appl., 1996; 682: 273-81.
11. Al-Gohary OMN, Foda NH. Availability of mebeverine hydrochloride from suppositories. Pharm. Ind., 1993; 55(4): 396-400.
12. Hosny EA, Abd-Elhady SS, El-Tahir KEH. Formulation, in vitro release and ex-vivo spasmolytic effects of mebeverine hydrochloride suppositories containing polycarbophil or polysorbate 80. Int. J. Pharm., 1996; 142: 163-68.
13. Abdel-Hady, S. S.; Mortada, N.; Awad, G. A.S.; Zaki, N. M.; Taha, R. A. In-vitro release and ex-vivo spasmolytic effects of mebeverine hydrochloride from rectal suppositories containing release enhancers. Egyp. J. Biomed. Sci., 2001; 7: 72-92.
14. Abdel-Hady S. S.; Mortada N. D.; Awad G. A. S.; Zaki N. M.; Taha R. A. Development of in situ gelling and mucoadhesive mebeverine hydrochloride solution for rectal administration. Saudi Pharm. J., 2003; 11 (4), 159-171.
15. Schmitt M, Guentert TW. Influence of hydrophilicity of suppository bases on rectal absorption of carprofen, a lipophilic non-steroidal anti-inflammatory drug. J. Pharm. Sci. 1990; 79: 357-63.
16. Vidras NJ, Reid VE, Bohidar NR, Plankogiannis M. Medicament release from suppository bases. I: Physiochemical characteristics and bioavailability of indomethacin in rabbits. J. Pharm. Sci., 1982; 71(8): 945-49.
17. Ibrahim S, El-Faham T, Shawkytous S, Mostafa E. Formulation, release characteristics and evaluation of ibuprofen suppositories. Int. J. Pharm., 1990; 61: 1-7.
18. Al-Angary AA, Khidr SH, Abd-Elhady SS, Bayomi MA, Mahrous GM. Sensitive high performance liquid chromatographic determination of mebeverine in plasma using fluorescence detection. Anal. Lett., 1992; 25(7): 1251-60.
19. Shah V, Midha K, Dighe S, McGilveray I, Skelly J, Yacobi A, Layloff T, Viswanathan C, Edgar Cook C, McDowall R, Pittman K, Spector S. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies. Pharm. Res., 1992; 9: 588-92.
20. El-Sayed Y, Al-Meshal M, Al-Angary A, Al-Balla S, Gouda MW. Effects of oral administration of cholestipol and cholestyramine on the pharmacokinetics of ketoprofen administered intramuscularly in man. Int. J. Pharm., 1994; 109 : 107-13.
21. Higuchi T. Mechanism of sustained-action medication, theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci., 1963; 52(12): 1145-9.
22. Ibrahim S, Abd-Elbary A, El-Sorady H, Abd Elmonem H. Availablity of oxyphenbutazone from different suppository formulations. Pharmazie 1980; 35, H.4: 213-16.
23. El-Assasy A, Soliman I, Farid S. Formulation and bioavailability of tiaprofenic acid suppositories. Bull. Fac. Pharm. Cairo Univ., 1997; 35(2): 151-7.
24. Fontan JE, Arnaud P, Chaymeil JC. Enhancing properties of surfactants on the release of carbamazepine from suppositories. v Int. J. Pharm., 1991; 73: 17-21.
25. Becirevic M, Petricic V, Kallay N. In vitro release of meclozine hydrochloride from lipophilic suppository bases with or without tensides. Pharmazie, 1984; 39, H.12: 828-30.
26. Ammar H, Omar S. Solubilization of carbamazepine by non-ionic surfactants. Pharmazie, 1994; 49: 746-8.
27. Othman S, Muti H. The effect of bases and formulation on the release of indomethacin from suppositories. Drug Dev. Ind. Pharm., 1986; 12: 1813-31.
28. Hammouda YE, Kasim NA, Nada AH. Formulation and in vitro evaluation of verapamil HCI suppositories. Int. J. Pharm. 1993; 89: 111-8.
29. Appel L, Zentner G. Use of modified ethylcellulose lattices for microporous coating of osmotic tablets. Pharm. Res.; 1991; 8(5): 60-4.
30. th edition, Lea & Febiger, Philadilphia, Pennsylvania, USA, 1991:124-145.
31. Sallai J, Vernyik A, Regdon G, Gombkoto S, Nemeth J, Regdon JR. Experiences with the rectal use of trimethoprim. J. Pharm. Pharmacol., 1997; 49: 496-99.
32. Kato Y, Matsushita T, Yokoyama T, Mohri K. Enhanced bioavailability of 6-mercaptopurine after rectal admin.in rats. Pharm. Res., 1992; 9(5): 697-99.
33. rd edition. Appleton-Century-Crofts, New York, USA, 1993: 15-20.
34. Nishihata T, Tomida H, Frederick G, Rytting H, Higuchi T. Comparison of the effects of sodium salicylate, disodium ethylene diamine tetra acetic acid and polyxyethylene-23-lauryl ether as adjuvants for the rectal absorption of sodium cefoxitin. J. Pharm. Pharmacol. 1985; 37: 159-63.
35. Davis SS, Burnham WR, Wilson P, O'Brien J. Use of adjuvants for enhancement of rectal absorption of cefoxitin in humans. Antimicrobial Agents and Chemotherapy, 1985; 28(2): 211-5.
36. Fix JA, Gardner CR. Rectal Drug Delivery: a viable alternative. Pharm. Int.; 1986; November: 272-5.
37. Niazy E. Influence of oleic acid and other permeation promoters on transdermal delivery of dihydroergotamine through rabbit skin. Int. J. Pharm. 1991; 67: 97-100.
38. Kim C, Kim J, Chi S, Shim C. Effect of fatty acids and urea on the penetration of ketoprofen through rat skin. Int. J. Pharm. 1993; 99: 109-18.
39. th Edition, Mack Publishing Company, Easton, Pennsylvania, 1990: 773.
40. Bates I. The blood-brain barrier and central nervous system drug penetration. Pharm. J. 1984; 232: 266-8.
41. De Boer AG, Moolenaar F, de Leede LG, Breimer DD. Rectal drug administration: Clinical pharmacokinetic considerations. Clin. Pharmacok., 1982; 7: 285-311.
42. Tokada K, Yoshikawa, H, Muranishi S. Partial avoidance of first-pass elimination of azathioprine in rats by rectal dosing. Int. J. Pharm.; 1985; 25: 155-63.